[go: up one dir, main page]

WO1998038985A2 - Medicament pour la prophylaxie et le traitement des maladies inflammatoires - Google Patents

Medicament pour la prophylaxie et le traitement des maladies inflammatoires Download PDF

Info

Publication number
WO1998038985A2
WO1998038985A2 PCT/EP1998/001240 EP9801240W WO9838985A2 WO 1998038985 A2 WO1998038985 A2 WO 1998038985A2 EP 9801240 W EP9801240 W EP 9801240W WO 9838985 A2 WO9838985 A2 WO 9838985A2
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
inflammatory
myocarditis
preventive
carvedilol
Prior art date
Application number
PCT/EP1998/001240
Other languages
English (en)
Other versions
WO1998038985A3 (fr
Inventor
Akira Matsumori
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Priority to AU69203/98A priority Critical patent/AU6920398A/en
Publication of WO1998038985A2 publication Critical patent/WO1998038985A2/fr
Publication of WO1998038985A3 publication Critical patent/WO1998038985A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the inventor of the present invention conducted various researches to achieve the foregoing objects. As a result, he found that, when ( ⁇ )-l-(carbazole-4-yloxy)-3[[2-(o- methoxyphenoxy)ethyl]amino]-2-propanol was administered to a mouse myocarditis model inoculated with Encephalomyocarditis (EMC) virus, necrosis of myocardial cells and infiltration of inflammatory cells to normal heart tissues were inhibited and pathological findings of myocarditis were remarkably improved The present invention was achieved on the basis of these findings.
  • EMC Encephalomyocarditis
  • carvedilol [( ⁇ )-l-(carbazole-4-yloxy)-3-[[2-(o-methoxy- phenoxy)ethyl]amino]-2-propanol] was used as the medicament of the present invention, and compared with metoprolol [l-(isopropylamino)-3-[p-( ⁇ -methoxyethyl)phenoxy]-2- propanol tartrate], which is known as a compound also having ⁇ -receptor blocking activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention a pour objet un médicament pour la prophylaxie et le traitement des maladies inflammatoires. Ce médicament comprend un ingrédient actif comme substance choisie dans le groupe se composant de carvedilol, d'isomères de ce dernier, actifs sur le plan optique, de ses dérivés hydroxy-carbazole et de sels pharmacologiquement acceptables de ces derniers.
PCT/EP1998/001240 1997-03-06 1998-03-05 Medicament pour la prophylaxie et le traitement des maladies inflammatoires WO1998038985A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69203/98A AU6920398A (en) 1997-03-06 1998-03-05 Medicament for preventive and therapeutic treatment of inflammatory diseas es

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP97/51473 1997-03-06
JP9051473A JPH10251147A (ja) 1997-03-06 1997-03-06 炎症性疾患の予防・治療剤

Publications (2)

Publication Number Publication Date
WO1998038985A2 true WO1998038985A2 (fr) 1998-09-11
WO1998038985A3 WO1998038985A3 (fr) 1998-12-23

Family

ID=12887931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001240 WO1998038985A2 (fr) 1997-03-06 1998-03-05 Medicament pour la prophylaxie et le traitement des maladies inflammatoires

Country Status (3)

Country Link
JP (1) JPH10251147A (fr)
AU (1) AU6920398A (fr)
WO (1) WO1998038985A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024198A1 (fr) * 2000-09-21 2002-03-28 University Of Houston Nouvelle therapie
US9539221B2 (en) 2003-10-09 2017-01-10 Egb Advisors, Llc Method of treating airway diseases with β-adrenergic inverse agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024198A1 (fr) * 2000-09-21 2002-03-28 University Of Houston Nouvelle therapie
US9539221B2 (en) 2003-10-09 2017-01-10 Egb Advisors, Llc Method of treating airway diseases with β-adrenergic inverse agonists

Also Published As

Publication number Publication date
JPH10251147A (ja) 1998-09-22
AU6920398A (en) 1998-09-22
WO1998038985A3 (fr) 1998-12-23

Similar Documents

Publication Publication Date Title
JP4846063B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
US6200958B1 (en) Agent for treating high-risk impaired glucose tolerance
KR20100016270A (ko) 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
JP3860226B2 (ja) ヒト免疫不全症ウイルス感染の予防または治療の方法
JP3007992B2 (ja) （ｒ）−アムロジピンによる平滑筋細胞の遊走の抑制
WO1998038985A2 (fr) Medicament pour la prophylaxie et le traitement des maladies inflammatoires
CA2088582A1 (fr) Medicament contre le diabete sucre
HUT71497A (en) New pharmaceutical use of 1,2,3,4,4a,5,10,10a-octahydro-benzo(g) quinoline derivatives
KR0137927B1 (ko) 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체
US20180064660A1 (en) Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
US5837709A (en) Use of castanospermine as an anti-inflammatory and immunosupressant agent
WO2005079792A1 (fr) Agents préventifs ou thérapeutiques pour la rétinopathie diabétique sévère
JP4126345B2 (ja) ウイルス感染症の予防・治療剤
US5426117A (en) N-methyl-2-(3-pyridyl)-tetrahydrothio-pyran-2-carbothioamide 1-oxide to the preparation of medicinal products intended for treatment of coronary insufficiency
JP2007291091A (ja) 角結膜障害治療剤
WO2008031358A1 (fr) 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers
JPH10120569A (ja) 眼疾患予防または治療剤
JPWO2021094563A5 (fr)
JP2000191535A (ja) 血管平滑筋細胞増殖に起因する疾患用薬
JPH09194360A (ja) 肝線維化防止剤
JPH10167961A (ja) 緑内障治療剤
WO2007114315A1 (fr) Agent therapeutique pour trouble corneen/conjonctival

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538161

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase